Latest News

Corporate Google and Sanofi partner in diabetes

Google and Sanofi partner in diabetes

The search giant and the drugmaker will develop new tools to monitor the disease and improve patient outcomes.

Corporate Five things for pharma marketers to know: Tuesday, September 1

Five things for pharma marketers to know: Tuesday, September 1

Amgen gives hefty discount to Repatha in Europe; Valeant partners with AstraZeneca on controversial psoriasis drug; Pfizer now offers single packages of Viagra

Data/Analytics Pharma sales forces should act more like 'outcomes advocates'

Pharma sales forces should act more like 'outcomes advocates'

Sales reps that focus on creating value for HCPs could find new opportunities and improved access to those physicians, according to Accenture.

Campaigns Five things for pharma marketers to know: Monday, August 31

Five things for pharma marketers to know: Monday, August 31

Kim Kardashian posts corrective information on Instagram and Twitter; DPP-4 inhibitors are linked to joint pain; doctors question off-label prescriptions of PCSK9 inhibitors

Payer/Managed Markets Five things for pharma marketers to know: Friday, August 28

Five things for pharma marketers to know: Friday, August 28

Amgen's Repatha receives FDA nod; Mylan shareholders vote in favor of Perrigo deal; doctors push for below-average price of experimental cancer drug

At Work With At Work With . . . Joe Doyle

At Work With . . . Joe Doyle

Pipeline The FDA approves second PCSK9 inhibitor, Repatha

The FDA approves second PCSK9 inhibitor, Repatha

Amgen's Repatha will come to market priced $500 lower than the cost of Sanofi and Regeneron's Praluent.

Campaigns Sunovion prepares for FDA decision on Aptiom

Sunovion prepares for FDA decision on Aptiom

The FDA is expected to announce this week whether it has approved the epilepsy drug as a monotherapy for partial-onset seizures.

Legal/Regulatory Five things for pharma marketers to know: Thursday, August 27

Five things for pharma marketers to know: Thursday, August 27

The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision

In Depth

In Depth

Social Engagement: Leveling the Field

Brand Development Strategies: Golden Oldies

Mobile Marketing: Dial M for Launch

Professional Ad Report: Staying Power

Therapeutic Focus: Women's Health

Back Talk: Is Cost Myopia Unfocused?

Private View: The Lions Share